Trial Profile
Clinical Evaluation of Lapatinib Administered With Capecitabine in Japanese Patients With ErbB2 Overexpressing Advanced or Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 25 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Feb 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 21 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.